AiCuris Anti-infective Cures AG

General information
AiCuris Anti-infective Cures AG
Friedrich-Ebert-Str. 475
Building 302
42117 Wuppertal, North Rhine-Westphalia
Germany

Contact person: Holger Zimmermann, Chief Executive Officer
Company main phone: +49 (202) 317630
Company main fax:  +49 (202) 317631177
Website:  www.aicuris.com
Year founded:2006
Source of foundation:Spin-off from company
Name of foundation source:Bayer Infection Research
Corporate description / mission:
AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the start of pivotal phase 3 development with its proprietary lead compound pritelivir, a novel helicase-primase inhibitor, following encouraging phase 2 interim results achieved in the phase 2 part of its clinical phase 2/3 trial, PRIOH-1. The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Proteins
  • Small molecules
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Infectious and parasitic diseases / infectiology / parasitology
Business model:
  • In-licensing
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase I:2
Phase II:1
Phase III:2
On the market:1
Description of products:
Prevymis® / Letermovir (AIC246)
A paradigm shift in HCMV prophylaxis

Pritelivir (AIC316)
Treating acyclovir-resistant HSV infection

AIC649 and HBV research approaches
Achieving cure from HBV infection

AdV research approaches
Adenovirus-specific treatment for ocular infections

Artilysins®
Treating life-threatening bacterial blood-stream infections


AIC649 and IMI CARE approaches
Combatting pandemic viruses such as SARS-CoV-2

AMR research approaches
Combatting rising Anti-microbial resistance (AMR)
Collaborations & Clients
Partnering strategy / collaborations:
The following compounds are currently open for out licensing and/or co-development with a strategic partner:

AIC649
Proprietary immune modulator and potential cure for chronic hepatitis B infection
X